Dmitry Gabrilovich, M.D., Ph.D.


The research of Gabrilovich laboratory is focused on study of myeloid cells in tumor microenvironment, regulation of immune responses and immune suppression in cancer as well as on the development of new effective cancer immunotherapeutics.

Specifically, they are working on several different but closely linked projects:

  • Investigation of the mechanism of defective function of professional antigen presenting cells - dendritic cells (DC) in cancer. These cells are responsible for the induction of antitumor immune response. However, their differentiation and function in cancer is severely affected. They are studying the role of cross-presentation in tumor associated immunity and the role of lipid  metabolism in negative regulation of cross-presentation;
  • Understanding the biology and mechanism of action of myeloid-derived suppressor cells (MDSC) that accumulate in cancer patients and tumor-bearing mice. These cells are shown to be one of the major factors in the development of tumor non-responsiveness. The Gabrilovich laboratory is studying the mechanisms of their expansion and differentiation, specifically focusing on the role of retinoblastoma (Rb) gene in this process. They also investigate the mechanisms of T-cell tolerance induced by MDSC and potential therapeutic approaches to eliminate MDSC in pre-clinical and clinical settings;
  • Investigation of the role of ER stress response in pathological function of myeloid cells in cancer. They are studying molecular mechanism regulating ER stress response and its biological consequences for immune suppressive activity of MDSC;
  • Investigation of the effect of tumor microenvironment on differentiation and function of myeloid cells including immature myeloid cells, tumor associated macrophages and dendritic cells. They are studying the role of different factors (tumor endothelium, cytokines, hypoxia) that could be responsible for abnormal differentiation and function of these cells in tumor milieu;
  • Investigation of the role of metabolism in MDSC migration and their contribution to tumor metastases;
  • Investigation of the role of reactive oxygen species (ROS) in tumor associated immune defects. They are trying to identify the molecular mechanisms of increased ROS production in myeloid cells in cancer and it potential effect on effector cells;
  • The Gabrilovich lab is involved in several clinical trials targeting MDSC in cancer